WuXi AppTec Co., Ltd. (2359.HK) HKSE

128.00

-1.7(-1.31%)

Updated at June 03 11:59AM

Currency In HKD

Key Executives

Name	Title	Pay	Year Born
Minzhang Chen	Co-CEO & Executive Director	19.37M	1969
Qing Yang	Co-CEO & Executive Director	19.37M	1969
Ge Li	Co-Founder, Executive Chairman, President & Chief Executive Officer	48.51M	1967
Zhaohui Zhang	Chief Operating Officer of China, Executive Vice President & Executive Director	9.35M	1969
Youchu Wang	Senior Vice President of API Early Phase Development	0	N/A
Tao Guo	Senior Vice President of RCS IPM	0	N/A
Ming Shi	Senior Vice President & Chief Financial Officer	0	1974
Ruijia Tang	IR Director	0	N/A
Feng Zhang	Senior Vice President of API Manufacturing	0	1977
Howard Wu	Senior Vice President of Legal Department & Human Resources Department	0	N/A

Name

Title

Pay

Year Born

Minzhang Chen

Co-CEO & Executive Director

19.37M

1969

Qing Yang

Co-CEO & Executive Director

19.37M

1969

Ge Li

Co-Founder, Executive Chairman, President & Chief Executive Officer

48.51M

1967

Zhaohui Zhang

Chief Operating Officer of China, Executive Vice President & Executive Director

9.35M

1969

Youchu Wang

Senior Vice President of API Early Phase Development

N/A

Tao Guo

Senior Vice President of RCS IPM

N/A

Ming Shi

Senior Vice President & Chief Financial Officer

1974

Ruijia Tang

IR Director

N/A

Feng Zhang

Senior Vice President of API Manufacturing

1977

Howard Wu

Senior Vice President of Legal Department & Human Resources Department

N/A

Description

WuXi AppTec Co., Ltd., an investment holding company, provides research, development, and manufacturing services to discover, develop, and manufacture small molecule drugs, and cell and gene therapies in the People's Republic of China, rest of Asia, the United States, Europe, and internationally. The company operates through six segments: WuXi Chemistry, WuXi Testing, WuXi Biology, WuXi ATU, WuXi DDSU, and Others. It offers contract research, development, and manufacturing organization services for new drug development from discovery to commercial covering various categories for various synthetic molecular modalities, including small molecules, oligonucleotides, peptides, and complex conjugates; and biology services and solutions that support stand-alone and integrated projects from target discovery to candidate selection and into the clinic. The company also provides seamless drug and medical device testing services from preclinical testing to clinical trials; an integrated end-to-end solution to accelerate time to market for cell and gene therapies; drug discovery services to pharmaceutical and biotech customers; and clinical research services. WuXi AppTec Co., Ltd. was founded in 2000 and is headquartered in Shanghai, the People's Republic of China.